|
Category
|
n = 1427
|
|---|
|
Status of antimicrobial use n (%)
|
573 (40.2)
|
|
Carbapenems use
|
288 (20.2)
|
|
3,4-Generation Cephalosporins, Quinolones
|
149 (10.4)
|
|
>14 inpatient days
| |
|
Glycopeptides use
|
136 (9.5)
|
|
Isolation of pathogenic microorganisms n (%)
|
854 (59.8)
|
|
Blood culture - positive
|
360 (25.2)
|
|
MRSA
|
334 (23.4)
|
|
ESBLs
|
73 (5.1)
|
|
P. aeruginosa
|
71 (5.0)
|
|
Acinetobacter baumannii
|
16 (1.1)
|
- MRSA: methicillin-resistant Staphylococcus aureus.
- ESBLs: extended spectrum beta-lactamase-producing organisms.
-
P. aeruginosa: Pseudomonas aeruginosa resistant to at least one among Carbapenems, Quinolones and Aminoglycosides.
